ES2723776T3 - Nuevas cepas de rotavirus humano y vacunas - Google Patents

Nuevas cepas de rotavirus humano y vacunas Download PDF

Info

Publication number
ES2723776T3
ES2723776T3 ES10775467T ES10775467T ES2723776T3 ES 2723776 T3 ES2723776 T3 ES 2723776T3 ES 10775467 T ES10775467 T ES 10775467T ES 10775467 T ES10775467 T ES 10775467T ES 2723776 T3 ES2723776 T3 ES 2723776T3
Authority
ES
Spain
Prior art keywords
amino acid
acid sequence
sequence seq
rotavirus
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10775467T
Other languages
English (en)
Inventor
Baoming Jiang
Roger I Glass
Yuhuan Wang
Jon Gentsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2723776T3 publication Critical patent/ES2723776T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición de vacuna para su uso en la inducción de una respuesta inmunológica contra un rotavirus en un sujeto, que comprende: un vehículo farmacéuticamente aceptable mezclado con una cepa de rotavirus aislada de CDC-9, la cepa de rotavirus de CDC-9 caracterizada por que es un rotavirus humano A, que tiene un genotipo P[8], G1, y una VP1 que tiene la secuencia de aminoácidos SEQ ID NO:17; una VP2 que tiene la secuencia de aminoácidos SEQ ID NO:20; una VP3 que tiene la secuencia de aminoácidos SEQ ID NO:23; una VP4 que tiene la secuencia de aminoácidos SEQ ID NO:26; una VP6 que tiene la secuencia de aminoácidos SEQ ID NO:29; una VP7 que tiene la secuencia de aminoácidos SEQ ID NO:32; una NSP1 que tiene la secuencia de aminoácidos SEQ ID NO:2; una NSP2 que tiene la secuencia de aminoácidos SEQ ID NO:5; una NSP3 que tiene la secuencia de aminoácidos SEQ ID NO:8; una NSP4 que tiene la secuencia de aminoácidos SEQ ID NO:11; y una NSP5 que tiene la secuencia de aminoácidos SEQ ID NO:14, o una VP1 que tiene la secuencia de aminoácidos SEQ ID NO:18; una VP2 que tiene la secuencia de aminoácidos SEQ ID NO:21; una VP3 que tiene la secuencia de aminoácidos SEQ ID NO:24; una VP4 que tiene la secuencia de aminoácidos SEQ ID NO:27; una VP6 que tiene la secuencia de aminoácidos SEQ ID NO:30; una VP7 que tiene la secuencia de aminoácidos SEQ ID NO:33; una NSP1 que tiene la secuencia de aminoácidos SEQ ID NO:3; una NSP2 que tiene la secuencia de aminoácidos SEQ ID NO:6; una NSP3 que tiene la secuencia de aminoácidos SEQ ID NO:9; una NSP4 que tiene la secuencia de aminoácidos SEQ ID NO:12; y una NSP5 que tiene la secuencia de aminoácidos SEQ ID NO:15.
ES10775467T 2009-05-12 2010-05-12 Nuevas cepas de rotavirus humano y vacunas Active ES2723776T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17739309P 2009-05-12 2009-05-12
PCT/US2010/034537 WO2010132561A2 (en) 2009-05-12 2010-05-12 New human rotavirus strains and vaccines

Publications (1)

Publication Number Publication Date
ES2723776T3 true ES2723776T3 (es) 2019-09-02

Family

ID=43085559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10775467T Active ES2723776T3 (es) 2009-05-12 2010-05-12 Nuevas cepas de rotavirus humano y vacunas

Country Status (8)

Country Link
US (6) US8822192B2 (es)
EP (2) EP3427750A1 (es)
CN (2) CN102695522B (es)
AU (1) AU2010249103B2 (es)
BR (1) BRPI1007721B1 (es)
CA (3) CA3121471A1 (es)
ES (1) ES2723776T3 (es)
WO (1) WO2010132561A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197487B1 (en) * 2007-09-04 2016-01-06 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Thermal inactivation of rotavirus
CA3121471A1 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
CN104812892B (zh) * 2012-08-27 2018-07-17 默多克儿童研究所 经修饰的人轮状病毒及其用途
CN103316336B (zh) * 2013-05-31 2015-01-28 北京科兴中维生物技术有限公司 一种适于口服的轮状病毒疫苗
LT3299384T (lt) * 2015-05-21 2021-12-27 Xiamen University Sutrumpintas rotaviruso vp4 baltymas ir jo pritaikymas
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine
EP3373965A1 (en) 2015-11-09 2018-09-19 CureVac AG Rotavirus vaccines
CN106916791B (zh) * 2015-12-25 2021-05-04 中国医学科学院医学生物学研究所 人轮状病毒毒种ztr-18毒株及其分离，培养及鉴定
BR112019003419A2 (pt) * 2016-08-26 2019-05-21 Serum Institute Of India Private Limited composição de vacina multivalente
US20220313813A1 (en) * 2019-06-18 2022-10-06 Curevac Ag Rotavirus mrna vaccine
CN113480617A (zh) * 2021-07-09 2021-10-08 山东威高利彤生物制品有限公司 轮状病毒毒株及其作为疫苗的用途
CN114940706B (zh) * 2022-04-20 2023-08-15 中国疾病预防控制中心病毒病预防控制所 一种人轮状病毒毒株、分离培养方法、鉴定及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
ES2121841T3 (es) 1990-11-16 1998-12-16 Childrens Hosp Medical Center Una vacuna para proporcionar proteccion inmunologica contra enfermedades de rotavirus en humanos.
US6780630B1 (en) 1992-07-10 2004-08-24 Baylor College Of Medicine Parenteral immunization against rotavirus
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5773009A (en) 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
KR100688434B1 (ko) 1998-07-28 2007-03-09 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 다가의 인간-소의 로타바이러스 백신
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
PT1212084E (pt) 1999-08-17 2006-07-31 Glaxosmithkline Biolog Sa Metodos para separar variantes do rotavirus e vacina do rotavirus vivo atenuado
US20030166139A1 (en) 2001-07-20 2003-09-04 Choi Anthony H. Rotavirus VP6 subunit
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
WO2006007555A2 (en) * 2004-07-01 2006-01-19 Children's Medical Center Corporation ¨ Rotavirus antigens
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2007008905A1 (en) 2005-07-11 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Porcine rotavirus reassortant compositions
EP2197487B1 (en) * 2007-09-04 2016-01-06 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Thermal inactivation of rotavirus
CA3121471A1 (en) * 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines

Also Published As

Publication number Publication date
WO2010132561A2 (en) 2010-11-18
AU2010249103B2 (en) 2015-02-26
US20200054735A1 (en) 2020-02-20
CN102695522A (zh) 2012-09-26
CA2763359C (en) 2021-07-27
US11786589B2 (en) 2023-10-17
CA3121471A1 (en) 2010-11-18
WO2010132561A3 (en) 2011-06-16
US11065327B2 (en) 2021-07-20
US20120121629A1 (en) 2012-05-17
US20170173144A1 (en) 2017-06-22
EP2429577A2 (en) 2012-03-21
US9974851B2 (en) 2018-05-22
US9498526B2 (en) 2016-11-22
CN102695522B (zh) 2016-10-19
US20180236060A1 (en) 2018-08-23
US8822192B2 (en) 2014-09-02
EP2429577A4 (en) 2013-11-06
US20150079122A1 (en) 2015-03-19
AU2010249103A1 (en) 2012-01-12
EP3427750A1 (en) 2019-01-16
CA3121654A1 (en) 2010-11-18
CN106421772A (zh) 2017-02-22
BRPI1007721B1 (pt) 2020-04-28
BRPI1007721A2 (pt) 2016-02-16
CA2763359A1 (en) 2010-11-18
AU2010249103A2 (en) 2012-03-01
EP2429577B1 (en) 2019-01-30
WO2010132561A8 (en) 2011-03-03
US20210308254A1 (en) 2021-10-07
US10500269B2 (en) 2019-12-10

Similar Documents

Publication Publication Date Title
ES2723776T3 (es) Nuevas cepas de rotavirus humano y vacunas
Crisci et al. Virus-like particles: the new frontier of vaccines for animal viral infections
Wei et al. Genetic reassortment of infectious bursal disease virus in nature
ES2700243T3 (es) Construcciones del virus de la enfermedad de Marek recombinantes no patógenas que codifican antígenos del virus de la laringotraqueitis infecciosa y del virus de la enfermedad de Newcastle
Wang et al. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
AR080515A1 (es) Vacunas recombinantes del virus de la enfermedad del pie y de la boca (fmd1) y sus usos
JP2015517304A5 (es)
NO20092340L (no) Antigenicity of infectious pancreatic necrosis virus VP2 sub-viral particles expressed in yeast
US20210269488A1 (en) Recombinant rotavirus expression system and recombinant rotaviruses
CN110904153A (zh) 表达非洲猪瘟病毒p12或p17蛋白的重组猪繁殖与呼吸综合征病毒的构建方法及其应用
Kingstad-Bakke et al. Effective mosaic-based nanovaccines against avian influenza in poultry
BR112020007213A2 (pt) construtos de vírus da doença de marek não patogênico recombinante que codificam múltiplos antígenos heterólogos
WO2011007339A3 (en) Chimeric foot and mouth disease viruses
Uprety et al. Recent advances in rotavirus reverse genetics and its utilization in basic research and vaccine development
AU2005279303A1 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
RU2015100269A (ru) Реассортантные btv и ahsv вакцины
Taniguchi et al. Genetics and reverse genetics of rotavirus
Jalilvand et al. Rotavirus VP6 preparations as a non-replicating vaccine candidates
Guo et al. Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens
Shoja et al. Formation of self‐assembled triple‐layered rotavirus‐like particles (tlRLPs) by constitutive co‐expression of VP2, VP6, and VP7 in stably transfected high‐five insect cell lines
Wang et al. The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review
Molinari et al. Production of rotavirus-like particles in Spodoptera frugiperda larvae
Yang et al. Reverse genetics approaches for live-attenuated vaccine development of infectious bursal disease virus
Marashi et al. Intra-peritoneal and intra-rectal immunogenicity induced by rotavirus virus like particles 2/6/7 in mice